

NeuClone Company Profile



A clinical-stage biopharmaceutical company focused on high quality, affordable biosimilars.

- Developing over 20 biosimilar mAb products
- Vision to provide affordable life-saving and life-extending therapies
- Vision made possible by 'Right from the Start[®]' biosimilar approach, including the NeuMAX[®] platform and industry leading analytical capabilities
- Two biosimilars successfully completed Phase I clinical development
- Lead biosimilar product referencing US\$8.0 billion Stelara[®] market
- Management has extensive global biopharma industry experience
- Seeking partners for development, manufacture and commercialization of biosimilar products

BIOSIMILAR PIPELINE

Originator	Product Category	Patent Expiry (EU/US)	2020 Sales (US\$bn) ¹	NeuClone Biosimilar Development Stage				
				Early pre-clinical	Late pre-clinical	Process scale-up	Phase I	Phase III
Stelara [®] (ustekinumab)	Autoimmune	2024/2023	\$8.0b	[Progress bar: Early pre-clinical to Phase I]				
Herceptin [®] (trastuzumab)	Breast cancer	2014/2019	\$4.0b	[Progress bar: Early pre-clinical to Phase I]				
Perjeta [®] (pertuzumab)	Breast cancer	2025/2025	\$4.2b	[Progress bar: Early pre-clinical to Process scale-up]				
Prolia/XGEVA [®] (denosumab)	Osteoporosis/ Oncology	2025/2025	\$5.1b	[Progress bar: Early pre-clinical to Process scale-up]				
Keytruda [®] (pembrolizumab)	Oncology	2030/2028	\$14.4b	[Progress bar: Early pre-clinical to Process scale-up]				
Synagis [®] (palivizumab)	RSV prevention	2015/2015	\$1.1b	[Progress bar: Early pre-clinical to Process scale-up]				
Humira [®] (adalimumab)	Autoimmune	2018/2023	\$20.4b	[Progress bar: Early pre-clinical to Process scale-up]				
Opdivo [®] (nivolumab)	Oncology	2030/2028	\$7.9b	[Progress bar: Early pre-clinical to Process scale-up]				
+12 additional products	-	-	-	[Progress bar: Early pre-clinical to Process scale-up]				

1) Source: La Merie (2021)

KEY DIFFERENTIATORS


NeuClone's 'Right from the Start[®]' development approach enables efficient production of high quality biosimilars at low cost by incorporating the NeuMAX[®] technology platform and industry leading analytic capabilities.

NeuMAX[®] Technology Platform

- 1) NeuPRO[™] Manufacturing process
- 2) NeuCHO[®] Host cell line
- 3) NeuMAX[™] Vectors Custom expression vectors

Enables low cost manufacture of biologics


NeuPRO[™] - Yield Comparison



Industry Leading Analytic Capabilities

NeuClone conducts extensive in-house analytical testing from the earliest stages and throughout development to ensure a high level of biosimilarity for NeuClone's products.

Deep in-house capabilities include cell based assays, X-ray crystallography analysis, glycosylation, potency and more.



NeuClone's X-ray crystallography overlay of Stelara[®] originator & NeuLara biosimilar

JOHN OKSINSKI: Head of Global Business Development and Alliances

PHONE: +612 9209 4020

EMAIL: j.oksinski@neuclone.com

WEBSITE: www.neuclone.com